SABCS 2021 | Detection of ctDNA post neoadjuvant chemo is associated with disease relapse in early breast cancer
Michail Ignatiadis, MD, PhD, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium, discusses the results of a single-center study evaluating the utility of a personalized circulating tumor DNA (ctDNA) assay. The detection of ctDNA post neoadjuvant chemotherapy is associated with disease relapse in early breast cancer supporting interventional trials in this setting. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.
Disclosures
Novartis, Invited Speaker and Advisory Board, Personal
Seattle Genetics, Other, Personal,
Independent monitoring committee Natera, Coordinating PI, Institutional, No financial interest
Pfizer, Coordinating PI, Institutional, Financial interest
Roche, Coordinating PI, Institutional, Financial interest
